New initiative may significantly increase drug prices for state tenders in Russia

14 February 2017

Prices for drugs under public procurements in Russia may significantly increase in the event of the implementation of the latest initiative of the Russian Ministry of Health for the conduction of purchases without specification of the release form, dosage or a type of packaging of the drug, but only generic name of the drug (a unique name for the active substance).

According to an official spokesman of the Russian Ministry of Health, the introduction of the new rules is mainly related with the launch of the IAS, which a new system for the monitoring of purchasing prices for drugs in Russia, reports The Pharma Letter’s local correspondent.

In the meantime, the new initiative has already been criticized by some leading pharmaceutical Russian industry associations, according to which it will reduce the effectiveness of treatment for local citizens, will increase the workload on doctors and lead to higher prices of drugs under state tenders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK